An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this trial is to allow continued access to pregabalin to Canadian
subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114
and 1008-164 and to continue to study the long term safety of pregabalin administered as
adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with
refractory partial seizures.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.